Oliver Dodd

Oliver Dodd is the Co-President and Treasurer at Nucleate. Oliver has also served as the CEO and Co-Founder at Remora Therapeutics and Research Associate at FVL59. Oliver's journey in the field of research started as an Undergraduate Research Assistant at Koch Institute for Integrative Cancer Research followed by a position as a Research Assistant at Center of Cancer Systems Biology. Oliver has also worked as a Research Assistant at Dana-Farber Cancer Institute. Oliver's work has been focused on investigating the mechanism of action of a novel CDK12/13 inhibitor in human neuroblastoma cells.

Oliver Dodd received a Doctor of Philosophy in Biology and Biomedical Sciences from Harvard University. Oliver also holds a Bachelor of Science in Biology from the Massachusetts Institute of Technology.